Surgery Partners (NASDAQ:SGRY) Cut to Hold at TD Cowen

TD Cowen downgraded shares of Surgery Partners (NASDAQ:SGRY) from a strong-buy rating to a hold rating in a research note released on Saturday morning,Zacks reports.

Other research analysts have also recently issued research reports about the company. Cantor Fitzgerald cut Surgery Partners from an “overweight” rating to a “hold” rating in a research report on Monday, October 26th. UBS Group downgraded shares of Surgery Partners from a “buy” rating to a “hold” rating and upped their price target for the company from $21.00 to $23.50 in a research note on Wednesday, October 28th. Weiss Ratings raised shares of Surgery Partners from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, October 16th. Stonex Financia lowered shares of Surgery Partners from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 27th. Finally, Benchmark reiterated a “buy” rating on shares of Surgery Partners in a research note on Tuesday, August 11th. Three equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Surgery Partners currently has an average rating of “Hold” and an average target price of $20.14.

Surgery Partners Trading Down 0.4%

Shares of NASDAQ:SGRY opened at $23.12 on Friday. Surgery Partners has a 12-month low of $11.41 and a 12-month high of $23.37. The business has a 50 day moving average of $15.30 and a 200-day moving average of $14.68. The company has a quick ratio of 1.78, a current ratio of 1.95 and a debt-to-equity ratio of 1.18. The stock has a market cap of $3.03 billion, a PE ratio of -33.03, a P/E/G ratio of 7.19 and a beta of 1.90.

Surgery Partners (NASDAQ:SGRY) last released its quarterly earnings results on Monday, August 10th. The company reported $0.10 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.04. The business had revenue of $848.90 million during the quarter, compared to analysts’ expectations of $830.03 million. Surgery Partners had a positive return on equity of 0.88% and a negative net margin of 2.63%. The firm’s revenue for the quarter was up 2.7% compared to the same quarter last year. During the same period last year, the firm posted $0.17 EPS. As a group, equities research analysts forecast that Surgery Partners will post 0.25 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Teresa DeLuca acquired 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The stock was acquired at an average cost of $14.35 per share, for a total transaction of $143,500.00. Following the completion of the acquisition, the director directly owned 66,843 shares of the company’s stock, valued at approximately $959,197.05. This trade represents a 17.59% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. 2.00% of the stock is owned by insiders.

Institutional Trading of Surgery Partners

Large investors have recently modified their holdings of the stock. Jupiter Topco LLC bought a new stake in Surgery Partners during the 2nd quarter valued at $233,220,000. Pentwater Capital Management LP purchased a new position in shares of Surgery Partners during the 2nd quarter valued at $195,384,000. BlackRock Inc. purchased a new stake in shares of Surgery Partners during the 2nd quarter valued at approximately $104,857,000. Hsbc Holdings PLC bought a new position in Surgery Partners in the 2nd quarter worth about $48,912,000. Finally, Bank of America Corp DE bought a new position in Surgery Partners in the 2nd quarter valued at $20,374,000.

Key Surgery Partners News

Here are the key news stories impacting Surgery Partners this week:

• Positive Sentiment: Bon Secours Mercy Health’s proposed $23.50-per-share acquisition provides a clear valuation reference and supports the share price. Bain Capital, Surgery Partners’ largest shareholder, plans to roll its equity into the combined company, signaling substantial shareholder participation. Surgery Partners stock enters take-private focus after HealthSpan deal
• Neutral Sentiment: The consensus price target was raised 15.45% to $22.61, reflecting improved valuation expectations, but the target is below the merger offer and therefore provides limited incremental support while the transaction remains pending. Surgery Partners consensus price target increased by 15.45% to $22.61
• Negative Sentiment: KeyCorp reduced its FY2026 EPS forecast to $0.07 from $0.16 and cut its FY2027 forecast to a $0.21-per-share loss from expected earnings of $0.13. It also lowered its Q3 2026 estimate to a $0.13 loss, while forecasting a $0.08 loss for Q4. These revisions point to weaker near-term profitability than previously expected.
• Negative Sentiment: Multiple law firms are investigating the $23.50 merger, including whether Surgery Partners’ directors breached fiduciary duties and whether the transaction adequately serves shareholders. Such investigations may increase deal uncertainty, although these notices do not by themselves indicate that wrongdoing occurred. SGRY shareholder merger investigation Scott+Scott Surgery Partners investor alert

About Surgery Partners

Surgery Partners, Inc is a U.S.-based healthcare services company that operates and manages ambulatory surgery centers and surgical hospitals. The company works with physicians, health systems and other healthcare providers to deliver outpatient surgical care in facilities designed for same-day procedures.

Its facilities provide surgical services across specialties such as orthopedics, pain management, ophthalmology, gastroenterology, urology, gynecology and general surgery. Surgery Partners also supports its operations with clinical, administrative and revenue-cycle services intended to help physicians and facility partners manage patient care and practice operations.

Founded in 2004 and headquartered in Brentwood, Tennessee, Surgery Partners has expanded its platform through acquisitions, joint ventures and other partnerships.